Patent · US Active

Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)

US10189856B2 · kind B2 · utility

3Cited by

12References

7Claims

0Family size

Assignee

Adverio Pharma GmbH · DE

Inventors

Claudia Hirth-Dietrich · Wuppertal, DE
Peter Sandner · Wuppertal, DE
Johannes-Peter Stasch · Wuppertal, DE
Andreas Knorr · Erkrath, DE
Georges Von Degenfeld · Leverkusen, DE
Michael Hahn · Langenfeld, DE
Markus Follmann

Key dates

Filing date	May 24, 2011
Grant date	Jan 29, 2019
Priority date	—
Expiry date	Dec 12, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.